LONDON, Dec 7 British drugmaker GSK said today its antibody-based Covid-19 therapy with US partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies. The data, yet to be published in a peer-reviewed medical.
The data, yet to be published in a peer-reviewed medical journal, shows the treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK says
British drugmaker GSK said on Tuesday its antibody based COVID 19 therapy with U.S. partner Vir Biotechnology is effective against all mutations of th.
The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.